Abstract
BackgroundInhibitors of the Renin-angiotensin-aldosterone-system (RAASi) offer prognostic advantages in heart failure with reduced ejection fraction (HFrEF), after myocardial infarction (MI) and for those with chronic kidney disease (CKD). Nevertheless, when...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
